Xin Lang Cai Jing·2025-12-16 12:51Group 1 - Fosun Pharma plans to acquire a controlling stake in Green Valley Pharmaceutical amid production halts and registration setbacks, attracting significant market attention [1][2] - The investment will be made by Fosun Pharma's subsidiary, Fosun Pharma Industrial Development Co., with a total investment of approximately 1.412 billion yuan to gain control of Green Valley [5][6] - The acquisition will result in Fosun Pharma holding 53% of Green Valley's shares, which will be consolidated into Fosun's financial statements [7][29] Group 2 - Green Valley Pharmaceutical has faced severe financial challenges, with total liabilities nearing 800 million yuan and a significant drop in revenue due to the suspension of its core product, GV-971 [12][40] - The company reported revenues of approximately 572 million yuan in 2024, with a net profit of 70.77 million yuan, but saw revenues plummet to about 102 million yuan in the first three quarters of 2025, resulting in a net loss of 67.61 million yuan [38][39] - Green Valley's operational issues have led to significant layoffs, with nearly 80% of its workforce facing job cuts due to the cessation of sales activities [42][43] Group 3 - GV-971, Green Valley's flagship product, was initially approved conditionally in November 2019 and became a prominent treatment for Alzheimer's disease, but its conditional approval is set to expire in November 2024 due to unmet post-marketing clinical trial requirements [15][37] - The drug's price was significantly reduced after being included in the national medical insurance directory, but its reliance on a single product has made the company vulnerable to regulatory pressures [15][37] - The ongoing challenges with GV-971's re-registration process and the recent regulatory scrutiny highlight the risks associated with the acquisition [26][56]